What DEXUS (ASX:DXS)'s Widening Full-Year Net Loss Means For Shareholders

• DEXUS has released its full-year results for the year ended 30 June 2026, reporting sales of A$29.9 million, revenue of A$459.23 million and a net loss of A$122.05 million.
• While sales increased year on year, the combination of lower overall revenue and a much larger loss per share highlights pressure on the group’s profitability and cost base.
• We’ll now examine how this sharp widening of DEXUS’s full-year net loss reshapes the company’s investment narrative and risk profile.

The latest GPUs need a type of rare earth metal called Neodymium and there are only 28 companies in the world exploring or producing it. Find the list for free.

DEXUS Investment Narrative Recap

To own DEXUS today, you need to believe its shift toward higher quality, diversified real assets and capital recycling can offset pressure in office and funds management earnings. The sharp move to a A$122.05 million full year loss and reduced revenue puts the near term focus squarely on whether disposals and development projects can support distributable income, while amplifying the key risk around elevated funding needs and the resilience of fee based revenues.

The most relevant recent announcement is the sale of 480 Queen Street in Brisbane for around A$700 million, as part of DEXUS’s broader office selldown. In light of the latest loss, this transaction looks increasingly central to the story: it crystallises capital, reduces CBD office exposure and potentially supports the balance sheet at a time when gearing, interest costs and development funding requirements sit at the heart of the risk and catalyst debate.

Yet behind the headlines, investors should also be aware of how ongoing redemption pressures and asset sales could interact with a weaker earnings base...

Read the full narrative on DEXUS (it's free!)

DEXUS' narrative projects A$952.7 million revenue and A$715.3 million earnings by 2029.

Uncover how DEXUS' forecasts yield a A$7.35 fair value, a 27% upside to its current price.

Exploring Other Perspectives

Before this result, the most optimistic analysts were assuming DEXUS could reach about A$1.1 billion in earnings on roughly A$1.2 billion of revenue, which sits in sharp contrast to the latest A$122.05 million loss and raises questions about how quickly the funds management and development pipelines can realistically offset ongoing office and financing risks.

Explore 3 other fair value estimates on DEXUS - why the stock might be worth just A$6.77!

Decide For Yourself

Don't just follow the ticker - dig into the data and build a conviction that's truly your own.

• A great starting point for your DEXUS research is our analysis highlighting 2 key rewards and 2 important warning signs that could impact your investment decision.
• Our free DEXUS research report provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate DEXUS' overall financial health at a glance.

Ready For A Different Approach?

These stocks are moving-our analysis flagged them today. Act fast before the price catches up:

• AI is about to change healthcare. These 7 stocks are working on everything from early diagnostics to drug discovery. The best part - they are all under $10b in market cap - there's still time to get in early.
• This technology could replace computers: discover 24 stocks that are working to make quantum computing a reality.
• Find 14 companies with promising cash flow potential yet trading below their fair value.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.